{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:38:23Z","timestamp":1790231903841,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejmech.2020.112175","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:41:38Z","timestamp":1582630898000},"page":"112175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Repurposed drug candidates for antituberculosis therapy"],"prefix":"10.1016","volume":"192","author":[{"given":"Qi","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112175_bib1","author":"WHO"},{"key":"10.1016\/j.ejmech.2020.112175_bib2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new End TB Strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2020.112175_bib3","first-page":"1960","article-title":"End the tuberculosis emergency: a promise is not enough","volume":"394","author":"The","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2020.112175_bib4","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2020.112175_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2020.112175_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.ejmech.2020.112175_bib7","first-page":"536","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study, the Lancet","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Infectious diseases"},{"key":"10.1016\/j.ejmech.2020.112175_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/s1806-37562017000000436","article-title":"New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis","volume":"44","author":"Silva","year":"2018","journal-title":"J.\u00a0Bras. Pneumol."},{"key":"10.1016\/j.ejmech.2020.112175_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2020.112175_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF01964300","article-title":"The clinical evaluation of antibacterial drugs: guidelines of the British Society for Antimicrobial Chemotherapy","volume":"9","author":"Finch","year":"1990","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF01964299","article-title":"Regulatory requirements for clinical evaluation of antimicrobial agents","volume":"9","author":"Christ","year":"1990","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2174\/1381612821666150310104416","article-title":"Drug repurposing for the treatment of staphylococcal infections","volume":"21","author":"Thangamani","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112175_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112175_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB \u2014 final study outcomes","volume":"373","author":"Lee","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.ejmech.2020.112175_bib16","article-title":"Evaluation of a rapid molecular drug-susceptibility test for tuberculosis","volume":"65","year":"2018","journal-title":"Indian J. Tubercul."},{"key":"10.1016\/j.ejmech.2020.112175_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4211-0","article-title":"Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres","volume":"19","author":"Riccardi","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/jac\/33.5.949","article-title":"In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms","volume":"33","author":"Chen","year":"1994","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib19","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1128\/AAC.01158-15","article-title":"Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus","volume":"59","author":"Kaushik","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nchembio.2237","article-title":"Non-classical transpeptidases yield insight into new antibacterials","volume":"13","author":"Kumar","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112175_bib21","first-page":"235","article-title":"Activities of biapenem against Mycobacterium tuberculosis in macrophages and mice","volume":"32","author":"Guo","year":"2019","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.ejmech.2020.112175_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12858-017-0082-4","article-title":"Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem","volume":"18","author":"Bianchet","year":"2017","journal-title":"BMC Biochem."},{"key":"10.1016\/j.ejmech.2020.112175_bib23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2133\/dmpk.23.434","article-title":"pharmacokinetics, Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia","volume":"23","author":"Sato","year":"2008","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2020.112175_bib24","first-page":"3579832","article-title":"In\u00a0vitro activity of beta-lactams in combination with beta-lactamase inhibitors against Mycobacterium tuberculosis clinical isolates","author":"Li","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2020.112175_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbrc.2019.12.020","article-title":"Structural and biochemical analyses of the LdtMt2-panipenem adduct provide new insights into the effect of the 1-beta-methyl group on carbapenems","volume":"523","author":"Wang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2020.112175_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2015.10.005","article-title":"Diminazene aceturate\u2014an antiparasitic drug of antiquity: advances in pharmacology & therapeutics","volume":"102","author":"da Silva Oliveira","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2020.112175_bib27","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.1021\/bi00031a019","article-title":"Berenil [1, 3-bis (4\u2019-amidinophenyl) triazene] binding to DNA duplexes and to a RNA duplex: evidence for both intercalative and minor groove binding properties","volume":"34","author":"Pilch","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112175_bib28","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1021\/ci5003872","article-title":"Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug repurposing strategies","volume":"54","author":"Hamza","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.112175_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejmech.2014.02.065","article-title":"Anti-mycobacterial activity of 1,3-diaryltriazenes","volume":"77","author":"Cappoen","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0306-3623(95)00003-J","article-title":"Molecular actions of ebselen\u2014an antiinflammatory antioxidant","volume":"26","author":"Schewe","year":"1995","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112175_bib31","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/ncomms3748","article-title":"Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen","volume":"4","author":"Favrot","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112175_bib32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1096\/fj.12-223305","article-title":"Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione","volume":"27","author":"Lu","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.ejmech.2020.112175_bib33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/acsinfecdis.6b00004","article-title":"Identifying and tackling emergent vulnerability in drug-resistant mycobacteria","volume":"2","author":"Padiadpu","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib34","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1039\/C9CC04145A","article-title":"Targeting the Mycobacterium tuberculosis transpeptidase Ldt Mt2 with cysteine-reactive inhibitors including ebselen","volume":"55","author":"de Munnik","year":"2019","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.ejmech.2020.112175_bib35","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1021\/acs.joc.7b00440","article-title":"Thermal and photoinduced copper-promoted C\u2013Se bond formation: synthesis of 2-Alkyl-1,2-benzisoselenazol-3(2H)-ones and evaluation against Mycobacterium tuberculosis","volume":"82","author":"Thanna","year":"2017","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.41.7.1413","article-title":"chemotherapy, Assessment of the pharmacodynamic properties of antimalarial drugs in\u00a0vivo","volume":"41","author":"White","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib37","article-title":"Novel pharmacological activity of artesunate and artemisinin: their potential as anti-tubercular agents","volume":"6","author":"Choi","year":"2017","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nchembio.2259","article-title":"Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence","volume":"13","author":"Zheng","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112175_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acschembio.8b00849","article-title":"Inhibiting Mycobacterium tuberculosis DosRST signaling by targeting response regulator DNA binding and sensor kinase heme","volume":"15","author":"Zheng","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112175_bib40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/1061186X.2017.1390671","article-title":"Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy","volume":"26","author":"Baruah","year":"2018","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ejmech.2020.112175_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijantimicag.2017.02.022","article-title":"Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux","volume":"50","author":"Matt","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112175_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw6635","article-title":"Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis","volume":"11","author":"Mishra","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2165\/00003495-199345030-00009","volume":"45","author":"Palmer","year":"1993","journal-title":"Mefloquine, Drugs"},{"key":"10.1016\/j.ejmech.2020.112175_bib44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1099\/jmm.0.058115-0","article-title":"Activity of antimalarial drugs in\u00a0vitro and in a murine model of cutaneous leishmaniasis","volume":"62","author":"Rocha","year":"2013","journal-title":"J.\u00a0Med. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112175_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.01392-10","article-title":"In\u00a0vitro and in\u00a0vivo efficacies of mefloquine-based treatment against alveolar echinococcosis","volume":"55","author":"Kuster","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib46","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Chemotherapy, mefloquine is active in\u00a0vitro and in\u00a0vivo againstMycobacterium avium complex","volume":"43","author":"Bermudez","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib47","first-page":"530815","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in\u00a0vitro and in macrophages","author":"Bermudez","year":"2014","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.ejmech.2020.112175_bib48","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.00321-2015","article-title":"Mefloquine as a potential drug against multidrug-resistant tuberculosis","volume":"46","author":"Krieger","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2020.112175_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","article-title":"Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection","volume":"48","author":"Rodrigues-Junior","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112175_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3109\/14756366.2014.930454","article-title":"Quinoline and quinolones: promising scaffolds for future antimycobacterial agents","volume":"30","author":"Singh","year":"2014","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib52","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/j.ejmech.2011.07.046","article-title":"Synthesis of 3-heteroarylthioquinoline derivatives and their in\u00a0vitro antituberculosis and cytotoxicity studies","volume":"46","author":"Chitra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib53","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.ejmech.2011.03.039","article-title":"New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents","volume":"46","author":"Thomas","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0035-9203(92)90414-8","article-title":"Hygiene, Studies on a new antimalarial compound: pyronaridine","volume":"86","author":"Chang","year":"1992","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2020.112175_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tube.2017.01.005","article-title":"Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I","volume":"103","author":"Ekins","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2020.112175_bib56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tube.2018.08.004","article-title":"The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase","volume":"112","author":"Mori","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2020.112175_bib57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00003495-198632050-00001","article-title":"Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy","volume":"32","author":"Campoli-Richards","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112175_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mehy.2018.04.002","article-title":"Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy","volume":"115","author":"Mishra","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejmech.2020.112175_bib59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Ping Dou","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2020.112175_bib60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI68101","article-title":"Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity","volume":"124","author":"Kagoya","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.112175_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00253-15","article-title":"Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria","volume":"6","author":"Moreira","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2020.112175_bib62","first-page":"61","article-title":"Towards selective mycobacterial ClpP1P2 inhibitors with reduced activity against the human proteasome","author":"Moreira","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cbdd.12091","article-title":"Boron-containing peptidomimetics--a novel class of selective anti-tubercular drugs","volume":"81","author":"Gorovoy","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112175_bib64","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/psc.2537","article-title":"Syntheses and anti-tubercular activity of beta-substituted and alpha,beta-disubstituted peptidyl beta-aminoboronates and boronic acids","volume":"19","author":"Gorovoy","year":"2013","journal-title":"J.\u00a0Pept. Sci."},{"key":"10.1016\/j.ejmech.2020.112175_bib65","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-08-0298","article-title":"Elesclomol induces cancer cell apoptosis through oxidative stress","volume":"7","author":"Kirshner","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112175_bib66","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/iub.2002","article-title":"The evaluation of the anti-cancer drug elesclomol that forms a redox-active copper chelate as a potential anti-tubercular drug","volume":"71","author":"Ngwane","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2020.112175_bib67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ejmech.2018.07.047","article-title":"Synthesis of carbohydrazides and carboxamides as anti-tubercular agents","volume":"156","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib68","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2174\/1570180815666180727120422","article-title":"Preparation and antitubercular activities of palindromic hydrazinecarbothioamides and carbonothioic Dihydrazides","volume":"16","author":"Hearn","year":"2019","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2020.112175_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-016-0431-4","article-title":"Diagnosis and treatment of childhood migraine","volume":"18","author":"Merison","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejmech.2020.112175_bib70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/11632850-000000000-00000","article-title":"Management of cluster headache","volume":"26","author":"Tfelt-Hansen","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2020.112175_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","article-title":"Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism","volume":"145","author":"Adams","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112175_bib72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/jiu095","article-title":"Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs","volume":"210","author":"Adams","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib73","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/jac\/dky091","article-title":"Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure","volume":"73","author":"Canezin","year":"2018","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib74","article-title":"Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps","volume":"8","author":"Ghajavand","year":"2019","journal-title":"Antimicrob. Resist. Infect. Contr."},{"key":"10.1016\/j.ejmech.2020.112175_bib75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00210-015-1169-3","article-title":"In\u00a0vitro and in\u00a0vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin","volume":"389","author":"Atil","year":"2016","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112175_bib76","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/jac\/dku166","article-title":"Simvastatin increases the in\u00a0vivo activity of the first-line tuberculosis regimen","volume":"69","author":"Skerry","year":"2014","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib77","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dkw014","article-title":"Statin adjunctive therapy shortens the duration of TB treatment in mice","volume":"71","author":"Dutta","year":"2016","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib78","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3389\/fmicb.2019.02097","article-title":"Simvastatin enhances the immune response against Mycobacterium tuberculosis","volume":"10","author":"Guerra-De-Blas","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112175_bib79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2125.1990.tb03626.x","article-title":"Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects","volume":"29","author":"Singhvi","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112175_bib80","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","article-title":"Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations","volume":"68","author":"Kyrklund","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2020.112175_bib81","article-title":"Adjunctive host-directed therapy with statins improves tuberculosis-related outcomes in mice","author":"Dutta","year":"2019","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.28250","article-title":"Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats","volume":"63","author":"Fernandez-Varo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2020.112175_bib83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gene.2019.01.029","article-title":"Drug repurposing against arabinosyl transferase (EmbC) of Mycobacterium tuberculosis: essential dynamics and free energy minima based binding mechanics analysis","volume":"693","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2020.112175_bib84","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6026\/97320630012368","article-title":"Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB","volume":"12","author":"Brindha","year":"2016","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2020.112175_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/5.Supplement_B.19","article-title":"Tetroxoprim--a new inhibitor of bacterial dihydrofolate reductase","volume":"5","author":"Aschhoff","year":"1979","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112175_bib86","first-page":"189","article-title":"L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug","volume":"24","author":"Goldstein","year":"2010","journal-title":"Cardiovascular Therapeutics"},{"key":"10.1016\/j.ejmech.2020.112175_bib87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12967-017-1363-9","article-title":"Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis","volume":"15","author":"Kaur","year":"2017","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib88","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.str.2013.09.022","article-title":"Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs","volume":"22","author":"Dias","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2020.112175_bib89","first-page":"931","article-title":"Molecular docking study of Mycobacterium tuberculosis dihydrofolate reductase in complex with 2, 4-diaminopyrimidines analogues","volume":"43","author":"Sittikornpaiboon","year":"2015","journal-title":"Chiang Mai J. Sci."},{"key":"10.1016\/j.ejmech.2020.112175_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101592","article-title":"Synthesis of 2,4-diaminopyrimidine core-based derivatives and biological evaluation of their anti-tubercular activities","volume":"22","author":"Ouyang","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112175_bib91","first-page":"E435","article-title":"Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK","volume":"111","author":"Liu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2020.112175_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/infdis\/jiz064","article-title":"Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects","volume":"220","author":"Lachmandas","year":"2019","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib94","doi-asserted-by":"crossref","first-page":"924","DOI":"10.5588\/ijtld.18.0687","article-title":"Metformin and tuberculosis risk in elderly patients with diabetes mellitus","volume":"23","author":"Park","year":"2019","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2020.112175_bib95","doi-asserted-by":"crossref","first-page":"32725","DOI":"10.1038\/srep32725","article-title":"Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice","volume":"6","author":"Shen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112175_bib96","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ijo.2009.132","article-title":"Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions","volume":"33","author":"Fong","year":"2009","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejmech.2020.112175_bib97","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2016.07.009","article-title":"Repurposing of a drug scaffold: identification of novel sila analogues of rimonabant as potent antitubercular agents","volume":"122","author":"Ramesh","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112175_bib98","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2019.01.003","article-title":"Crystal structures of membrane transporter MmpL3, an anti-TB drug target","volume":"176","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112175_bib99","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/open.201900227","article-title":"Design and synthesis of imidazole and triazole pyrazoles as Mycobacterium tuberculosis CYP121A1 inhibitors","volume":"8","author":"Kishk","year":"2019","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.ejmech.2020.112175_bib100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1753-4887.2008.00040.x","article-title":"Update on alpha-linolenic acid","volume":"66","author":"Stark","year":"2008","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.ejmech.2020.112175_bib101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.apjtm.2016.01.021","article-title":"Evaluation of anti-tubercular activity of linolenic acid and conjugated-linoleic acid as effective inhibitors against Mycobacterium tuberculosis","volume":"9","author":"Choi","year":"2016","journal-title":"Asian Pacific Journal of Tropical Medicine"},{"key":"10.1016\/j.ejmech.2020.112175_bib102","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0091-6749(98)70083-1","article-title":"P.M.J.J.o.A. O\u2019Byrne, C. Immunology, Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early-and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects","volume":"102","author":"Hamilton","year":"1998","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2020.112175_bib103","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708038","article-title":"An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: implications to a novel combinatorial therapy","volume":"10","author":"Mishra","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1126\/science.6429854","article-title":"Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug","volume":"225","author":"Tepperman","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112175_bib105","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1504022112","article-title":"Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis","volume":"112","author":"Harbut","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2020.112175_bib106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40261-013-0063-3","article-title":"A\u00a0multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study","volume":"33","author":"Zhang","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejmech.2020.112175_bib107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6026\/97320630012368","article-title":"Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB","volume":"12","author":"Brindha","year":"2016","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2020.112175_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41522-018-0075-0","article-title":"Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention","volume":"5","author":"Kumar","year":"2019","journal-title":"npj Biofilms and Microbiomes"},{"key":"10.1016\/j.ejmech.2020.112175_bib109","first-page":"1041","article-title":"Cyclosporin A: a powerful immunosuppressant","volume":"126","author":"Laupacis","year":"1982","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.ejmech.2020.112175_bib110","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1038\/s41467-019-10744-6","article-title":"A\u00a0genome-wide positioning systems network algorithm for in silico drug repurposing","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112175_bib111","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.molcel.2019.04.001","article-title":"Metabolomics-driven exploration of the chemical drug space to predict combination antimicrobial therapies","volume":"74","author":"Campos","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2020.112175_bib112","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.287.5460.1960","article-title":"Drug discovery: a historical perspective","volume":"287","author":"Drews","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112175_bib113","author":"FDA"},{"key":"10.1016\/j.ejmech.2020.112175_bib114","author":"Drugbank"},{"key":"10.1016\/j.ejmech.2020.112175_bib115","author":"MCE"},{"key":"10.1016\/j.ejmech.2020.112175_bib116","author":"Selleck"},{"key":"10.1016\/j.ejmech.2020.112175_bib117","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00253-15","article-title":"Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria","volume":"6","author":"Moreira","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.ejmech.2020.112175_bib118","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","article-title":"Network-based approach to prediction and population-based validation of in silico drug repurposing","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112175_bib119","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112175_bib120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","article-title":"Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes","volume":"571","author":"Johnson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112175_bib121","doi-asserted-by":"crossref","first-page":"872","DOI":"10.15252\/msb.20156777","article-title":"Chemogenomics and orthology-based design of antibiotic combination therapies","volume":"12","author":"Chandrasekaran","year":"2016","journal-title":"Mol. Syst. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:06:57Z","timestamp":1759327617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420301422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":121,"alternative-id":["S0223523420301422"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112175","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposed drug candidates for antituberculosis therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112175"}}